in the united stat	ES PATENT	AND TRADEMARK OFFICE
Application of)	
)	Examiner: Mitra, R.
Glenn J. DORIN et al.)	
G:-1 N 00/00C 500)	Group Art Unit: 1653
Serial No.: 09/996,588)	Atty. Dkt. No.: 012441.00013
Filed: November 30, 2001)	PP-01009.106

For: FORMULATION, SOLUBILIZATION, PURIFICATION, AND REFOLDING OF TISSUE FACTOR

PATHWAY INHIBITOR

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

U.S. Patent and Trademark Office 220 20th Street S. Customer Window, Mail Stop Amendment Crystal Plaza Two, Lobby, Room 1B03 Arlington, VA 22202

Sir:

In accordance with 37 C.F.R. §§ 1.97 and 1.98, attached is a Form PTO 1449 citing references for the Examiner's consideration. Please charge the fee of \$180 to our Deposit Account No. 19-0733. If this amount is incorrect, please debit or credit our Deposit Account No. 19-0733.

By:

11/17/2004 AADOFO1 00000002 09996588

01 FC:1806

180.00 DA

Respectfully submitted,

BANNER & WITCOFF, LTD.

Date: November 16, 2004

Customer No. 22907

Lisa M. Hemmendinger

Registration No. 42,653

PTO/SB/08b(08-03)

Approved for use through 07/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

ubstitute for form 1449B/PTO

NOV 1 6 2004

PADEMEN'S

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

2 Sheet 2 of

Complete if Known				
Application Number	09/996,588			
Filing Date	November 30, 2001			
First Named Inventor	Glenn J. Dorin			
Art Unit	1653			
Examiner Name	Rita Mitra			
Attorney Docket Number	012441.00013			

NON PATENT LITERATURE DOCUMENTS				
Examiner Initials *	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	Τ²	
		Rainer Rudolph, "Successful Protein Folding on a Industrial Scale", Protein Engineering: Principles and Practice, Chapter 10, pps. 283-298, dated 1996		
		Rudolph & Lillie, "In vitro folding of inclusion body proteins", Folding of Acidic Fibroblast Growth Factor, FASEB J., 10, pps. 49-56, date unknown		
		Dabora et al., "Effect of Polyanions on the Refolding of Human Acidic Fibroblast Growth Factor", The Journal Of Biological Chemistry, Vol. 266, No. 35, pps. 23637-23640, dated December 15, 1991		
		Bernhard Fisher et al., "Isolation, Renaturation, and Formation of Disulfide Bonds of Eukaryotic Proteins Expressed in Escherichia coli as Inclusion Bodies, Biotechnology and Bioengineering, Vol. 41, pps. 3-13, dated 1993		
		J. Harenberg, et al., "Tissue factor pathway inhibotor: proposed heparin recognition region, Blood Coagulation and Fibrinolysis, Vol. 6, Supp. No. 1, pps. S50-S56, dated 1995		
		Mark E. Gustafson et al., "Renaturation and Purification of Human Tissue Factor Pathway Inhibitor Expressed in Recombinant E. coli, Protein Expression and Purification, Vol. 5, pps. 233-241, dated 1994		

Examiner	Date	
Signature	Considered	

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation in not in conformance and not considered. Include copy of this form with next communication to applicant.

Applicant's unique citation designation number (optional). Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 120 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO Complete if Known Application Number 09/996,588 INFORMATION DISCLOSURE Filing Date November 30, 2001 STATEMENT BY APPLICANT First Named Inventor Glenn J. Dorin Art Unit 1653 (Use as many sheets as necessary) Examiner Name Rita Mitra 012441.00013 Sheet 1 of 2 Attorney Docket Number

	U.S. PATENT DOCUMENTS					
Examiner Cite	Cite	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of	Pages, Columns, Lines, Where Relevant	
Initials *	Cite No. ¹	Number - Kind Code ² (if known)		Cited Document	Passages or Relevant Figures Appear	
		US- 5,276,015				
		US-				
		US-				
	L	US-				
		US-				
		US-		1		
		US-				
		US-				
		US-	·			
		US-				
		US-				
		US-				
		US-				
		US-		1		
		US-				
		US-				
		US-				
		US-				
		US-				
		US-				

FOREIGN PATENT DOCUMENTS						
Examiner	Cite	Foreign Patent Document Publication		Name of Patentee or	Pages, Columns, Lines,	
Initials*	No.1	Country Code ³ - Number ⁴ - Kind Code ⁵ (<i>if known</i>)	Date MM-DD-YYYY	Applicant of Cited Document	Where Relevant Passages or Relevant Figures Appear	T ⁶
		EP 0473 564 A1	3/4/92			
		EP 0 559 632 A2	9/8/93			
		EP 0 325 691	8/2/89			
		EP 0 131 864	1/23/85			•
		WO 93/25230A1	12/1993			

Examiner Signature	Date Considered	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. Applicant's unique citation designation number (optional). See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.